ERBB2 and breast carcinoma: In summary, we show evidence that activated AMPK negatively regulates HER2 and EGFR signaling by phosphorylating both of these proteins at novel regulatory sites, leading to inhibition of growth and survival of breast cancer cells that are dependent on these pathways.